← All trials
NCT05004324
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- Aug 13, 2021
- Last posted
- Aug 13, 2021
- Enrollment
- 308
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kang Stem Biotech Co., Ltd.Lead sponsor
- Seoul National UniversityOverall official - principal investigator
- Konkuk UniversityOverall official - principal investigator
- Chosun UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Eulji UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.